ABVX:EPA
Abivax SA
၈၂.၁၀ €
arrow_upward
+၁.၄၈%(+၁.၂၀) 1D
အောက် ၆, GMT+၂ ၁၁:၀၄:၃၀ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
၈၁.၇၅ €
High
၈၂.၄၀ €
Low
၈၁.၅၀ €
Mkt. cap
၇၁၈.၆၂ ဋေ
Avg. vol.
၁.၅၇ သိန်း
Volume
၈.၇၀ ထောင်
52-wk high
၁၃၉.၀၀ €
52-wk low
၆၀.၄၅ €
EPS
-၅.၂၀ €
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
Open
၈၁.၇၅ €
High
၈၂.၄၀ €
Low
၈၁.၅၀ €
Mkt. cap
၇၁၈.၆၂ ဋေ
Avg. vol.
၁.၅၇ သိန်း
Volume
၈.၇၀ ထောင်
52-wk high
၁၃၉.၀၀ €
52-wk low
၆၀.၄၅ €
EPS
-၅.၂၀ €
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
News stories
From web sources and news partners
Axios
·
ပြီးခဲ့သည့် ၁၈ မိနစ်
Wall Street is on track for record profits
Enidnews.com
·
ပြီးခဲ့သည့် ၁ နာရီ
Everli, a Leading Italian E-Grocery Marketplace, Advances Toward Nasdaq Listing as SEC Declares Registration Statement Effective
Reuters
·
ပြီးခဲ့သည့် ၁၈ မိနစ်
Wall Street profits soar to $45.9 billion in first half of 2026, report shows
Stocktwits
·
ပြီးခဲ့သည့် ၂ နာရီ
US Real Estate Stocks Hit All-Time Low Relative To S&P 500, Prompting Peter Schiff’s ‘Industry Is Dead’ Warning
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees၉၈
Founded၂၀၁၃ ဒီ ၄
Headquarters-
Sector-
Websiteabivax.com